
SARS-CoV-2 coronavirus variants B.1.351 and P.1 escape from neutralizing antibodies
“In contrast, entry of the B.1.351 and P.1 variant was partially (Casirivimab) or fully (Bamlanivimab) resistant to antibodies used for COVID-19 treatment. Moreover, entry of these variants was less efficiently inhibited by plasma from convalescent COVID-19 patients and sera from BNT162b2-vaccinated individuals. These results suggest that SARS-CoV-2 may escape neutralizing antibody responses, which has important implications for efforts to contain the pandemic.”
Photo by Mufid Majnun on Unsplash
** This post was originally published on April 11, 2021 **